Optimi Health Corp. (OPTH) AI Stock Analysis

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. It produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. In addition, the company engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. Optimi Health sells its products online, through the Amazon marketplace, and via distributors and brokers.

Annual revenue increased from $80,717 in FY2022 to $426,904 in FY2025, reflecting a 3-year revenue CAGR of 74.2%. Annual revenue grew 124.3% in FY2023, 115.3% in FY2024, and 9.5% in FY2025. However, gross margin moved from 69.5% in FY2024 to -486.4% in FY2025. Operating margin remained negative across reported years, finishing at -1062.3% in FY2025 alongside a net income of -$3.7M. Over the trailing twelve months ended June 30, 2026, revenue totaled $175,671, with quarterly revenue declining 28.6% year-over-year, an operating margin of -957.8%, and EPS of -$1.56.

As of June 30, 2026, Optimi Health held $9.2M in cash and short-term investments alongside total debt of $3.6M, leaving net cash of $5.6M. Shareholders' equity was $12.4M against total assets of $18.2M, with a current ratio of 1.73 and a debt-to-equity ratio of 0.29. Operating cash flow in FY2025 was -$2.6M, and free cash flow was -$2.7M after capital expenditures of $88,375. Over 5 years, the company's share count increased 84.2%.

At a last close of $3.38 on October 16, 2026, Optimi Health had a market cap of $19.4M and an enterprise value of $22.9M. The stock trades at a price-to-sales multiple of 110.2x and an EV to revenue multiple of 183.4x, both significantly above the median of its US-listed Healthcare peers, which trades at a price-to-sales multiple of 4.1x. Its price-to-book multiple is 2.3x. Over the past year, OPTH shares dropped 59.0%, while the S&P 500 (SPY) gained 16.8%. Over 5 years, the stock fell 79.5% compared to an 83.0% increase for the S&P 500.

For the current fiscal year ending September 30, 2026, revenue is estimated at $665,740. For the next fiscal year, estimates project revenue of $1.2M, representing expected year-over-year revenue growth of 82.7%. The company recorded a net income of -$3.7M in FY2025 and trailing twelve months EPS of -$1.56. Optimi Health is scheduled to report its next earnings on November 13, 2026.

This page is an AI-written research summary of Optimi Health Corp. (OPTH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OPTH income statement, OPTH balance sheet, OPTH key metrics, OPTH analyst forecast, OPTH chart. See the OPTH stock overview for the latest quote and news.